US Biosimilar Outlook: Inspections, Interchangeability And Positioning For The Post-Humira Era

 
• By Bridget Silverman

Six of the 10 biosimilar candidates under FDA review are waiting on inspections delayed by COVID-19; in the meantime, sponsors jockey for position when Humira biosimilar launch windows open up next year.

health technology
• Source: Alamy

More from Complete Response Letters

More from Product Reviews